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Abstract
Background: High-density lipoprotein cholesterol (HDL-C) exerts many anti-atherogenic properties including its
role in reverse cholesterol transport (RCT). Scavenger receptor class B member 1 (SCARB1) plays a key role in RCT
by selective uptake of HDL cholesteryl esters. We aimed to explore the genetic contribution of SCARB1 to affecting
lipid levels in African Blacks from Nigeria.
Methods: We resequenced 13 exons and exon-intron boundaries of SCARB1 in 95 individuals with extreme HDL-C
levels using Sanger method. Then, we genotyped 147 selected variants (78 sequence variants, 69 HapMap tagSNPs,
and 2 previously reported relevant variants) in the entire sample of 788 African Blacks using either the iPLEX Gold
or TaqMan methods. A total of 137 successfully genotyped variants were further evaluated for association with
major lipid traits.
Results: The initial gene-based analysis demonstrated evidence of association with HDL-C and apolipoprotein A-I
(ApoA-I). The follow-up single-site analysis revealed nominal evidence of novel associations of nine common variants
with HDL-C and/or ApoA-I (P < 0.05). The strongest association was between rs11057851 and HDL-C (P = 0.0043), which
remained significant after controlling for multiple testing using false discovery rate. Rare variant association testing
revealed a group of 23 rare variants (frequencies ≤1 %) associated with HDL-C (P = 0.0478). Haplotype analysis
identified four SCARB1 regions associated with HDL-C (global P < 0.05).
Conclusions: To our knowledge, this is the first report of a comprehensive association study of SCARB1 variations
with lipid traits in an African Black population. Our results showed the consistent association of SCARB1 variants
with HDL-C across various association analyses, supporting the role of SCARB1 in lipoprotein-lipid regulatory
mechanism.
Keywords: African continental ancestry group, Candidate gene association study, Genetic variation, Haplotypes,
Lipids, SCARB1 protein, human, Sequence analysis, DNA
Background
Abnormal lipid and lipoprotein levels are a major risk
factor for coronary heart disease (CHD) [1], the leading
cause of death worldwide [2]. Elevated low-density
lipoprotein cholesterol (LDL-C) levels and decreased
high-density lipoprotein cholesterol (HDL-C) levels are
correlated with the development of CHD. There is a
strong genetic basis for lipoprotein-lipid levels with her-
itability estimates of 40–80 % [3]. A large number of
genes and genetic variants associated with lipid traits
have been discovered in genome-wide association stud-
ies (GWAS) [4–6]. Most of the common variants (minor
allele frequency [MAF] ≥5 %) identified by GWAS have
modest effects on lipid levels, and have overall a small
contribution to total genetic variance of lipid traits
(~25–30 % of the heritability) [4–8]. A portion of the
missing heritability of lipid traits could be explained by
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low frequency (LoF)/rare variants (MAF <5 %) as sug-
gested by recent studies [9–11].
HDL, the smallest and densest (d = 1.063–1.21 g/mL)
class of lipoprotein particles, has a variety of anti-
atherogenic properties [12]. One of the HDL properties
to protect against CHD is mediated by reverse choles-
terol transport (RCT) from peripheral tissues back to
the liver [13]. Scavenger receptor class B member 1
(SCARB1, protein; SCARB1, gene) serves as a HDL-C
receptor in RCT that mediates selective uptake of
HDL-C cholesteryl esters (CE) by the liver and free
cholesterol efflux from cells to HDL-C [14]. SCARB1 is
also implicated in the metabolism of apolipoprotein B
(ApoB)-containing particles [15–21].
The SCARB1 gene (Entrez Gene ID: 949) is located on
human chromosome 12, and is abundantly expressed in
liver and steroidogenic tissues [22, 23]. The role of
SCARB1 in HDL-C and ApoB-containing lipoproteins
metabolism has been established in animal studies. The
disruption of SCARB1 is associated with increased HDL-
C levels and decreased CE uptake [24–26]. Whereas the
overexpression of SCARB1 reduces levels of HDL-C,
ApoA-I, very low-density lipoprotein cholesterol (VLDL-
C), LDL-C, and ApoB [15–17, 19] and promotes the
hepatic uptake of CE as well as the biliary secretion of
HDL-C [15, 27]. The SCARB1 expression is also signifi-
cantly associated with hepatic VLDL-triglycerides (TG)
and VLDL-ApoB production. Hepatic VLDL cholesterol
production together with VLDL clearance is enhanced in
response to SCARB1 overexpression [21]. In contrast,
reduced hepatic VLDL-TG and VLDL-ApoB production
is associated with SCARB1 knockout status [18, 20, 21].
In humans, three SCARB1 mutations (rs397514572
[p.Ser112Phe], rs187831231 [p.Thr175Ala], and
rs387906791 [p.Pro297Ser]; MIM: 601040) have been
reported to be associated with significantly increased
HDL-C levels [28, 29]. Moreover, several genetic studies
have demonstrated the association of common SCARB1
variation with lipoprotein-lipid levels [5, 28–39] and sub-
clinical atherosclerosis [40].
To our knowledge, no genetic study has exclusively
investigated the association between SCARB1 and lipid
traits in native African populations to date. The object-
ive of this study was to resequence all 13 exons and
exon-intron boundaries of SCARB1 in 95 African
Blacks from Nigeria with extreme HDL-C levels for
variant discovery and then to genotype selected variants
in the entire sample of 788 African Blacks, followed by
genotype-phenotype association analyses with five major
lipid and apolipoprotein (Apo) traits (HDL-C, LDL-C, TG,
ApoA-I and ApoB). Because our initial gene-based ana-
lysis demonstrated evidence of association with HDL-C




The present study was carried out on 788 African Black
subjects from Benin City, Nigeria, who were recruited as
part of a population-based epidemiological study on
CHD risk factors. Detailed information on the study de-
sign and population description is provided elsewhere
[41]. In brief, 788 recruited subjects were healthy civil
servants (37.18 % females) from three government min-
istries of the Edo state in Benin City, Nigeria, aged
between 19 and 70 years, including 464 junior staff
(non-professional staff with salary grades 1–6), and 324
senior staff (professional and administrative staff with
salary grades 7–16). The summary features, including
biometric and quantitative data of the entire sample of
788 subjects are given in Table 1 and Additional file 1:
Table S1.
For resequencing, 95 individuals with extreme HDL-
C levels (within the upper and lower 10th percentiles of
HDL-C distribution) were chosen from the entire sample
of 788 African Blacks. Resequencing sample comprised of
48 individuals with high HDL-C levels (≥90th percentile,
range 68.30–99.00 mg/dL; Table 1) and 47 individuals
with low HDL-C levels (≤10th percentile, range 10.30–
35.00 mg/dL; Table 1). The University of Pittsburgh Insti-
tutional Review Board approved the study protocol. All
participants gave their informed consent.
Lipid and apolipoprotein measurements
At least 8-hour fasting blood samples were collected
from all participants. Serum specimens were separated
by centrifugation of blood samples and then stored at
−70 °C for 6–12 months until ready for testing. Lipid
and apolipoprotein measurements included total choles-
terol, HDL-C, TG, ApoA-I, and ApoB and were done
with standard assays at the Heinz Nutrition Laboratory,
University of Pittsburgh under the Centers for Disease
Control Lipid Standardization Program [41]. LDL-C was
calculated with the Friedewald equation [42] when TG
levels were less than 400 mg/dL.
PCR and sequencing
Genomic DNA was isolated from clotted blood using
the standard DNA extraction procedure. All 13 SCARB1
exons (isoform 1, NM_005505), exon-intron boundaries,
and 1 kb of each of 5′ and 3′ flanking regions on
chromosome 12 (hg19, chr12: 125,262,175-125,348,519)
were polymerase chain reaction (PCR) amplified and
sequenced. Specific primers were designed using the Pri-
mer3 software (Whitehead Institute for Biomedical
Research, http://bioinfo.ut.ee/primer3-0.4.0/) to cover 13
target regions, resulting in 14 amplicons, including two
overlapping amplicons for the largest last exon 13. PCR
reaction and cycling conditions are available upon request.
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The primer sequences and amplicon sizes are given in
Additional file 2: Table S2.
Automated DNA sequencing of PCR products was
performed in a commercial lab (Beckman Coulter
Genomics, Danvers, MA, USA) using Sanger method
and ABI 3730XL DNA Analyzers (Applied Biosystems,
Waltham, MA, USA). Variant analysis was performed
using Variant Reporter (version 1.0, Applied Biosys-
tems, Waltham, MA, USA) and Sequencher (version
4.8, Gene Codes Corporation, Ann Arbor, MI, USA)
software in our laboratory.
Variant selection for genotyping
Of 83 variants identified in the discovery step (see
Additional file 3: Table S3, Additional file 4: Table S4,
Additional file 5: Figure S1, and Additional file 6: Figure
S2), 78 (28 with MAF ≥5 % and 50 with MAF <5 %) were
selected based on the pairwise linkage disequilibrium (LD)
and Tagger analysis using an r2 threshold of 0.90 (5 were
excluded due to high LD) in Haploview (Broad Institute of
MIT and Harvard, https://www.broadinstitute.org/scien-
tific-community/science/programs/medical-and-popula-
tion-genetics/haploview/haploview) [43] for follow-up
genotyping in the entire sample (n = 788). Since our se-
quencing was focused primarily on coding regions, in
addition we selected 69 HapMap tag single nucleotide
polymorphisms [SNPs] (out of total 108 HapMap
tagSNPs; see Additional file 7: Table S5 and Additional file
8: Figure S3) based on Tagger analysis (MAF ≥5 % and
r2 ≥ 0.80) of HapMap data (Release #27) from the Yoruba
people of Ibadan, Nigeria (YRI), in order to cover the en-
tire gene for common genetic variation information.
Moreover, we selected two SCARB1 variants previously
reported to be significantly associated with lipid traits
in the literature (Additional file 9: Table S6). Conclu-
sively, a total of 149 variants, comprising of 78 se-
quence variants, 69 common HapMap-YRI tagSNPs,
and two relevant associated variants, were selected for
follow-up genotyping.
Genotyping
Genotyping of selected variants in the total sample of
788 individuals was performed by using either iPLEX
Gold (Sequenom, Inc., San Diego, CA, USA) or TaqMan
(Applied Biosystems, Waltham, MA, USA) methods and
following the manufacturers’ protocols.
Out of 149 selected variants, two failed assay designs
and nine failed genotyping runs (see details in Additional
file 3: Table S3, Additional file 7: Table S5, and Additional
file 9: Table S6). Quality control (QC) measures for suc-
cessfully genotyped variants were as follow: a genotype
call rate of ≥90 %, a discrepancy rate of <1 in 10 %
replicates, and no deviation from Hardy-Weinberg
equilibrium [HWE] (P >3.62 × 10−4 after Bonferroni
correction). Ultimately, a total of 137 QC-passed geno-
typed variants were included in genetic association ana-
lyses (see Additional file 9: Table S6, Additional file 10:
Table S7, Additional file 11: Figure S4, and Additional
file 12: Figure S5).
Statistical analysis
We used the Haploview program to determine allele fre-
quencies, to test HWE for genotype distribution, and to
evaluate the LD and pairwise correlations (r2) between
variants [43].
Table 1 Characteristics and lipid profile of 95 individuals with extremea HDL-C levels and of the entire sample of 788 African Blacks
95 Individuals with Extremea HDL-C Levels The Entire Sampleb
Variables High HDL-C Group Low HDL-C Group Pd
(HDL-C rangec: 68.30–99.00 mg/dL) (HDL-C rangec: 10.30–35.00 mg/dL)
N (Females, n) 48 (24) 47 (24) 1.00 788 (293)
Age, years 41.29 ± 8.72 40.87 ± 7.12 0.80 40.95 ± 8.39
BMI, kg/m2 22.06 ± 4.70 23.91 ± 5.51 0.08 22.87 ± 4.04
Total Cholesterol, mg/dL 201.00 ± 39.68 141.68 ± 31.03 2.40E-12 172.01 ± 38.47
LDL-Cholesterol, mg/dL 112.55 ± 39.75 95.04 ± 28.28 0.02 109.25 ± 34.40
HDL-Cholesterol, mg/dL 76.05 ± 7.53 25.51 ± 5.66 2.20E-16 47.88 ± 12.87
Triglycerides, mg/dL 61.98 ± 19.85 95.79 ± 73.21 0.004 72.96 ± 39.32
Apolipoprotein A-I, mg/dL 166.04 ± 28.19 103.84 ± 27.23 2.20E-16 137.03 ± 28.46
Apolipoprotein B, mg/dL 66.00 ± 20.22 69.64 ± 21.46 0.40 66.98 ± 22.19
BMI body mass index, HDL-C/HDL-Cholesterol high-density lipoprotein cholesterol, LDL-Cholesterol low-density lipoprotein cholesterol
Values are presented as unadjusted means ± standard deviation (SD), unless otherwise mentioned
aDistribution of HDL-C was adjusted for sex and age: HDL-C levels ≥90th % tile defined as the “High HDL-C group”, and HDL-C levels ≤10th % tile defined as the
“Low HDL-C group”
bAll data were unadjusted and included individuals with missing values or outliers (values beyond mean ± 3.5 SD)
cUnadjusted range values
dUnadjusted P-values were calculated with t-test or χ2 test depending on types of variables
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The values of each lipid phenotype outside the mean ±
3.5 standard deviation (SD) were excluded from down-
stream gene-based, single-site, and haplotype analyses.
However, the extreme phenotypic values associated with
rare variants (MAF ≤1 %) were maintained during rare
variant analysis, as was the case for the p70201/
chr12:125279319 variant (see study workflow in Fig. 1).
Values of the five lipid and apolipoprotein traits—HDL-
C, LDL-C, TG, ApoA-I, and ApoB—were transformed
using the Box-Cox transformation. For each trait, we
used stepwise regression method to select the most par-
simonious set of covariates from the following list: sex,
age, body mass index, waist, current smoking (yes/no),
minutes of walking or biking to work each day (jobmin),
and occupational status (staff: junior [non-professional
staff]/senior [professional and administrative staff]).
Genetic association analyses, including gene-based,
single-site, LoF/rare variant, and haplotype association
Fig. 1 Summary of the study design and flow. Chart presents an overview of the study design and flow, including sequencing and genotyping
stages and analysis approaches. ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LD, linkage
disequilibrium; LDL-C, low-density lipoprotein cholesterol; LoF, low-frequency; MAF, minor allele frequency; SD, standard deviation; SKAT-O, an
optimal sequence kernel association test; SNP, single nucleotide polymorphism; TG, triglycerides; YRI, Yoruba people of Ibadan from Nigeria
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tests, were performed using linear regression models
that included significant covariates for each variable
(Additional file 13: Table S8).
The gene-based association analysis was conducted under
linear additive model for the combined evaluation of com-
mon and LoF/rare variants (n = 136, excluding p70201/
chr12:125279319; see details above in paragraph two of this
section) for five major lipid traits using the versatile gene-
based association study [VEGAS] (http://gump.qimr.e-
du.au/VEGAS/) software [44]. The significance threshold
for the gene-based test was set at P-value of 0.05.
Following gene-based analysis, which primarily impli-
cated SCARB1 in regulation of HDL-C and ApoA-I
levels, we further elucidated the association of SCARB1
variants with these two traits using additional tests. In
single-site association analysis, P-values for each trait
were adjusted for multiple testing using Benjamini-
Hochberg procedure [45] to determine the false discov-
ery rate [FDR] (q-value). For common variants (MAF
≥5 %), a nominal P-value of <0.05 was considered to be
suggestive evidence of association, and an FDR cut-off
of 0.20 was used to define statistical significance. For LoF/
rare variants (MAF <5 %), the single-site association re-
sults were interpreted separately because of inadequate
power of our study to detect individual statistical signifi-
cance for these variants.
We conducted an optimal sequence kernel association
test (SKAT-O) [46] to evaluate the association between a
total of 43 LoF/rare variants (MAF <5 %) and the two lipid
traits (HDL-C and ApoA-I) by using three different MAF
thresholds: <5 % (n = 43), ≤2 % (n = 26), and ≤1 % (n = 23).
A significant SKAT-O test was set at a P-value of <0.05.
Haplotype association analysis was performed using
the generalized linear model. We applied a fixed sliding
window approach that included four variants per win-
dow and sliding for one variant at a time. For each win-
dow, a global P-value was used to assess the association
between the haplotypes with frequency >1 % and a given
trait. A global P-value threshold of 0.05 was used to
define significant haplotype association.
All analyses, except for VEGAS, were performed using
the R statistical software (http://www.r-project.org/) and
relevant R packages (i.e., Haplo.Stats for haplotype ana-
lysis and SKAT for SKAT-O analysis).
Results
Identification and distribution of SCARB1 sequence
variants in 95 individuals with extreme HDL-C levels
Resequencing of SCARB1 exons and exon-intron bound-
aries plus flanking regions in 95 African Blacks with ex-
treme HDL-C levels identified 83 variants, of which 51
had MAF <5 % (Additional file 3: Table S3 and Additional
file 5: Figure S1). The majority of 83 variants (n = 73) were
previously identified (dbSNP build 139: GRCh37.p10).
Most variants (n = 80) were singlenucleotide variations
[SNVs] (67 transitions and 13 transversions); the rest (n =
3) were short insertion and deletion variations (indels).
Tagger analysis using an r2 cutoff of 0.9 identified 28
bins for 32 common variants (MAF ≥5 %), of which three
included more than one variant (r2 ranging from 0.95 to
1.0) (Additional file 6: Figure S2). One of these three bins
contained two variants (rs204901986 and rs34339961) in
complete LD (r2 = 1.0). Of 51 LoF/rare variants (MAF
between 1 and 5 %, n = 31; MAF ≤1 %, n = 20), 17 were
present only in the high HDL-C group (MAF ranging
between 0.010 and 0.042) and eight were observed only in
the low HDL-C group (MAF ranging between 0.011 and
0.033). In the high HDL-C group, 29 of 48 (~60 %) indi-
viduals cumulatively carried at least one LoF/rare variant,
ranging from 1 to 7 variants. Similarly, in the low HDL-C
group, 27 of 47 (~57 %) individuals carried at least one
LoF/rare variant, ranging from 1 to 9 variants.
Most variants (n = 60) from our sequencing were lo-
cated in intronic regions, of which two (rs113910315,
MAF = 0.005 and rs10396210, MAF = 0.138) were within
splice sites (defined as ± 20 bp from the start or end of
an exon). The former splice site variant was observed
only in the low HDL-C group.
Of the total eight coding variants observed, four were
common variants (rs2070242 [p.Ser4Ser], rs10396208
[p.Cys21Cys], and rs5888 [p.Ala350Ala], and rs701103
[p.Gly499Arg]—3′ untranslated region [UTR] in isoform
1 and exon 13 in isoform 2), and the remaining four
were LoF/rare variants (rs4238001 [p.Gly2Ser], rs5891
[p.Val135Ile], rs5892 [p.Phe301Phe], and rs141545424
[p.Gly501Gly]). Of note, two LoF/rare coding variants,
(rs5891 [p.Val135Ile] and rs141545424 [p.Gly501Gly]),
were found only in the high HDL-C group.
Fifteen variants were located in either UTRs (n = 5)
or flanking regions (n = 10). One 3′ UTR variant
(rs150512235, MAF = 0.006) was very close to a predicted
microRNA-145 (miR-145) target site (TargetScanHuman
version 6.2, http://www.targetscan.org/). One 5′ flanking
variant (rs181338950, MAF = 0.048) was located in the
putative promoter region [47].
All 10 novel variants (9 SNVs and 1 insertion) identi-
fied in this study have been submitted to dbSNP data-
base ([batch ID: SCARB1_AB]:
http://www.ncbi.nlm.nih.gov/SNP/snp_viewTable.cgi?-
handle=KAMBOH) and were non-coding with MAF <5 %
(ranging between 0.005 and 0.011; Additional file 4: Table
S4). Of these novel variants, six and four were present
only in the high and low HDL-C groups, respectively.
Genotyping of SCARB1 variants in the entire sample of
788 individuals
Since our sequencing was focused primarily on coding re-
gions, we selected additional HapMap tagSNPs from the
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HapMap-YRI data in order to cover the entire SCARB1
gene for common genetic variation in SCARB1. Altogether
we selected 149 variants for genotyping in our entire
African Black sample as follows: 78 variants (28 common
variants and 50 LoF/rare variants) discovered in the se-
quencing step (Additional file 3: Table S3, Additional file
5: Figure S1, and Additional file 6: Figure S2), 69 common
HapMap-YRI tagSNPs (Additional file 7: Table S5), and
two additional variants with reported association in the
literature (Additional file 9: Table S6).
Of these 149 variants, 11 (10 from sequencing, including
one promoter [rs181338950], one coding (rs4238001
[p.Gly2Ser]), and one novel [p87459/chr12:125262061],
and 1 from HapMap tagSNPs [rs4765180]) failed genotyp-
ing, and one (rs866793 from HapMap tagSNPs) failed QC
measures. Thus, a total of 137 variants (Additional file 9:
Table S6 and Additional file 11: Figure S4) that passed QC
were advanced into association analyses with five
lipoprotein-lipid traits.
The majority of 137 genotyped variants (n = 120)
were located in introns, 11 were in exons, and six
were in 3′ flanking region (Table 2 and Additional
file 12: Figure S5). Ninety-four of 137 variants had
MAF ≥5 %, including four coding variants, one UTR
variant, two deletions, and one splice site variant. The
remaining 43 variants had MAF <5 % (MAF between
1 and 5 %, n = 20; MAF ≤1 %, n = 23), including three
coding variants, three UTR variants, one insertion,
and one splice variant.
Of the 10 novel variants discovered in the sequencing
step, nine (8 SNVs and 1 insertion) with MAF <1 % were
successfully genotyped (Additional file 4: Table S4).
There was one individual with plasma HDL-C levels
above the mean + 3.5 SD carrying one novel
variant—p70201/chr12:125279319 (MAF = 0.0010). Al-
though this extreme HDL-C value was excluded as out-
lier from the gene-based, single-site, and haplotype
analyses, it was included in the SKAT-O rare variant
analysis considering a possible large effect size of this
variant (Fig. 1).
Gene-based association analyses
Gene-based tests revealed a nominally significant asso-
ciation (P = 0.0421; Table 3) of SCARB1 variants with
HDL-C levels (best SNP: rs141545424 [p.Gly501Gly],
exon 12, MAF = 0.0007, P = 0.0016). Additionally, a
trend for association (P = 0.1016) was also observed for
ApoA-I levels (best SNP: rs7134858, intron 6, MAF =
0.1560, P = 0.0052).
Table 2 Distribution of 137 SCARB1 genotyped variants
Total MAF ≥5 % MAF between 1-5 % MAF ≤1 %
N (%) n (%) n (%) n (%)
Total variants 137 (100.00) 94 (68.61) 20 (14.60) 23 (16.79)
By known/novela
Known 128 (93.43) 94 (68.61) 20 (14.60) 14 (10.22)
Single-nucleotide variation 126 92 20 14
Short indels 2 2
Novel 9 (6.57) 9 (6.57)
Single-nucleotide variation 8 8
Short indels 1 1
By location
Exons-codingc 7 4c 1 2
Exons-UTRs 4 1 1 2
Introns 118 85 16 17
Introns-splice sitesb 2 1 1
3′ flanking 6 3 2 1
By amino acid change
Non-synonymousc 2 1c 1
Synonymous 5 3 1 1
Indels insertion and deletion variations, MAF minor allele frequency, UTR untranslated region
The list of 137 genotyped variants is shown in Additional file 9: Table S6
The list of 10 novel variants is shown in Additional file 4: Table S4
adbSNP build 139: GRCh37.p10. All 10 novel variants identified in this study have been submitted to dbSNP (batch ID:
SCARB1_AB): http://www.ncbi.nlm.nih.gov/SNP/snp_viewTable.cgi?handle=KAMBOH
bSplice site, defined as ± 20 bp from the start or end of an exon
cIncluding rs701103 (p.Gly499Arg; MAF = 0.2451) that is located in exon 13-3′ UTR and translated only in isoform 2
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Since the gene-based tests showed evidence of associa-
tions with HDL-C and ApoA-I, we primarily focused on
these two traits to further examine the SCARB1 variants
in the entire sample of 788 African Blacks.
Single-site association analyses of common SCARB1
variants
Of 94 common SCARB1 variants with MAF ≥5 %, 10
showed nominal associations (P < 0.05) with HDL-C and/
or ApoA-I (Table 4; see results for each trait in Additional
file 14: Table S9 and Additional file 15: Table S10), of
which three (rs11057851, rs4765615, and rs838895) exhib-
ited associations with both HDL-C and ApoA-I.
The most significant association was found between
rs11057851 and HDL-C (β =−0.5924, P = 0.0043, FDR =
0.1465). The second best association was between
rs7134858 and ApoA-I (β = 1.7537, P = 0.0052, FDR =
0.2918), followed by the association of rs5888 (p.Ala350Ala)
with ApoA-I (β = 2.0962, P = 0.0080, FDR = 0.2918).
Of 10 variants that showed nominal associations,
high LD (r2 > 0.80) was observed for two pairs of vari-
ants (Fig. 2), between rs8388912 and rs5888 (p.Ala350Ala;
r2 = 0.86), and between rs838896 and rs838895 (r2 = 0.84).
Association analyses of low-frequency/rare SCARB1
variants
The LoF/rare variants (n = 43) were categorized into
three groups based on their frequencies for association
analysis with HDL-C and ApoA-I using SKAT-O: MAF
<5 % (n = 43), MAF ≤2 % (n = 26), and MAF ≤1 % (n =
23). Although no association between LoF/rare variants
and ApoA-I was detected, the group of 23 variants with
MAF ≤1 % yielded nominal association with HDL-C
levels (P = 0.0478; Table 5).
We then individually examined the association of 23 vari-
ants with MAF ≤1 % with HDL-C and ApoA-I. Six of these
rare variants showed association with either HDL-C levels
or both HDL-C and ApoA-I levels (Table 6). While three of
them are known variants (rs115604379, rs377124254, and
rs141545424 [p.Gly501Gly]), the other three are novel
(p52919/chr12:125296601, p54611/chr12:125294909, and
p54856/chr12:125294664). Moreover, four of these six
rare variants (rs377124254, rs141545424 [p.Gly501Gly],
p54611/chr12:125294909, and p54856/chr12:125294664)
were present in individuals with extreme phenotypic
values (above or below the 3rd percentile). Two of
these variants (rs377124254: β = 11.5518, P = 0.0016;
rs141545424 [p.Gly501Gly]: β = 11.585, P = 0.0016)
were found in a single subject who had very high
HDL-C level. Whereas the other two were observed
in one individual each, who had extremely low HDL-
C levels (p54611/chr12:125294909: β = −9.5243, P = 0.0097;
p54856/chr12:125294664: β = −8.4305, P = 0.0215) and
ApoA-I levels (p54611/chr12:125294909: β = −19.3821, P =
0.0344; p54856/chr12:125294664: β =−24.0757, P = 0.0082).
This rare variant group also included a novel variant
(p70201/chr12:125279319) that was observed in one indi-
vidual with an unusually high plasma HDL-C level (above
the mean + 3.5 SD).
Haplotype association analyses
The 4-SNP sliding window haplotype analyses revealed
associations of 32 haplotype windows with HDL-C and/
or ApoA-I (global P < 0.05; Table 7; see results for each
trait in Additional file 16: Table S11), of which five (win-
dows #47, #72, #111, #112, and #123) were associated
with both.
Overall, a total of 21 haplotype windows showed signifi-
cant associations with ApoA-I, of which 10 contained
seven variants associated with ApoA-I in single-site ana-
lysis. Haplotype window #110 spanning introns 10–11
showed the best association signal (global P = 0.0012) and
contained the rs838896 variant with a nominal evidence
of association with ApoA-I (P = 0.0278) in single-site
analysis.




(n) SNP Namea-SNP IDb MAF P
HDL-C 136 207.5483 0.0421 p82264-rs141545424 0.0007 0.0016
LDL-C 136 134.1860 0.4640 p32777-rs11057841 0.2805 0.0047
TG 136 118.1598 0.6700 p86316-rs701104 0.0487 0.0357
ApoA-I 136 183.5565 0.1016 p55963-rs7134858 0.1560 0.0052
ApoB 136 143.7284 0.3760 p22116-rs12370382 0.0645 0.0153
ApoA-I apolipoprotein A-I, ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, MAF minor allele frequency, SNP
single nucleotide polymorphism, TG triglycerides
All results were adjusted for covariates: sex, age, body mass index, waist, current smoking (yes/no), minutes of walking or biking to work each day (jobmin), and
occupational status [staff: junior (non-professional staff)/senior (professional and administrative staff)]
Nominally significant gene-based P-values (P < 0.05) are shown in bold
aRefSeq of SCARB1: hg19, NM_005505 (CHIP Bioinformatics)
bdbSNP build 139: GRCh37.p10
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p20207 rs11057853 125329313 Intron 1 5 G/A 0.4484 0.4082 0.1925 1.0650 0.0343 0.4235
p20741 rs11057851 125328779 Intron 1 5 C/T 0.3237 −0.5924 0.2067 1.3010 0.0043 0.1465 ApoA-I (↓) Top 1
p45516 rs1902569 125304004 Intron 1 5 G/A 0.1544 0.5447 0.2629 0.6390 0.0386 0.4375
p49690 rs4765615 125299830 Intron 2 5 G/A 0.4426 −0.4646 0.1866 0.9330 0.0130 0.2526 ApoA-I (↓)
p79828 rs838895 125269692 Intron 11 5 C/G 0.3171 0.4961 0.2059 0.8220 0.0162 0.2756 ApoA-I (↑)
ApoA-I
p20741 rs11057851 125328779 Intron 1 5 C/T 0.3237 −1.2331 0.5117 0.8600 0.0162 0.3186 HDL-C (↓)
p49690 rs4765615 125299830 Intron 2 5 G/A 0.4426 −0.9139 0.4614 0.6770 0.0480 0.5022 HDL-C (↓)
p55963 rs7134858 125293557 Intron 6 6 C/T 0.1560 1.7537 0.6260 1.0710 0.0052 0.2918 Top 2
p63483 rs838912 125286037 Intron 7 7 G/A 0.0867 1.8700 0.8230 0.6880 0.0234 0.3972
p64772 rs5888 125284748 Exon 8 Ala350Ala 3a C/T 0.0961 2.0962 0.7888 0.9460 0.0080 0.2918 Top 3
p79721 rs838896 125269799 Intron 11 5 G/C 0.3104 1.1147 0.5056 0.7270 0.0278 0.4197
p79828 rs838895 125269692 Intron 11 5 C/G 0.3171 1.2206 0.5074 0.7800 0.0164 0.3186 HDL-C (↑)
p83884 rs701106 125265636 Intron 12 5 C/T 0.2597 1.2967 0.5352 0.7770 0.0156 0.3186
ApoA-I apolipoprotein A-I, FDR false discovery rate, HDL-C high-density lipoprotein cholesterol, MAF minor allele frequency, RegDB RegulomeDB, SE standard error, SNP single nucleotide polymorphism, UTR untranslated
region, R2, the proportion of the phenotypic variance explained by the variant; ↓, decreased; ↑, increased
Alleles on reverse strand. HDL-C and ApoA-I variables were in mg/dL and Box-Cox transformed
Results were adjusted for covariates: sex, age, waist, current smoking (yes/no), and minutes of walking or biking to work each day (jobmin) for HDL-C; sex and age for ApoA-I
The most significant P-value for each trait is shown in bold, see the single-site association (−log10 P) plot and pairwise correlations (r
2) in Fig. 2
FDR that reached a threshold of <0.20 is shown in bold
a, cRefSeq of SCARB1: hg19, NM_005505 (CHIP Bioinformatics)
bdbSNP build 139: GRCh37.p10














Fig. 2 Single-site P-values of 94 SCARB1 common variants for HDL-C and ApoA-I. Top: The -log10 P-values are presented in the Y-axis. A total of 94
genotyped variants with MAF ≥5 % are shown on SCARB1 gene (5′→ 3′; RefSeq: hg19, NM_005505) in the X-axis. The dash line indicates the
nominal significance threshold (P = 0.05). Middle: Gene structure of SCARB1. Bottom: Linkage disequilibrium (LD) plot of 10 SCARB1 variants with
P-values <0.05. Shades and values (r2 × 100) in each square of LD plot indicate pairwise correlations: black indicating r2 = 1, white indicating r2 = 0,
and shade intensity indicating r2 between 0 and 1. Marker names are shown as “SNP name-SNP ID”. SNP ID is based on dbSNP build 139. ApoA-I,
apolipoprotein A-I; FDR, false discovery rate; HDL-C, high-density lipoprotein cholesterol; LD, linkage disequilibrium; MAF, minor allele frequency; SNP,
single nucleotide polymorphism; UTR, untranslated region
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A total of 16 haplotype windows yielded significant
associations with HDL-C, of which seven contained
three HDL-C-associated variants detected in single-site
analysis. The most significant association was found
with window #111 (global P = 0.0040) spanning intron
11, which contained the rs838895 variant nominally asso-
ciated with HDL-C (P = 0.0162) in single-site analysis.
We observed nine regions (5 regions for ApoA-I and 4
regions for HDL-C) harboring consecutive significant
haplotype windows (global P < 0.05; ranging from 2 to 6
windows per region; Table 8 and Fig. 3). Seven of those
regions contained at least one of the six variants that ex-
hibited nominal associations (P < 0.05) with HDL-C and/
or ApoA-I (rs4765615, rs7134858, rs838912, rs838896,
rs838895, and rs701106) in single-site analysis.
Functional evaluation of identified variants
In order to examine the possible regulatory function of
all 153 SCARB1 variants (83 variants identified by our
sequencing, 68 common HapMap tagSNPs [excluding
rs4765180 due to genotyping failure; see Additional file
7: Table S5], and two relevant variants from the litera-
ture), we used the RegulomeDB database (version 1.0,
Stanford University, http://www.regulomedb.org/) [48].
Although most of 153 variants (n = 132) revealed scores
ranging from 1 to 6, only 11 were supported by strong
evidence for regulatory function (scores of 1f -2b): one
promoter, one 5′ UTR, two coding (rs2070242 [p.Ser4-
Ser] and rs10396208 [p.Cys21Cys]), five intronic, one 3′
UTR, and one 3′ flanking variants. Summary and de-
tailed regulatory functions are provided in Additional file
17: Table S12 and Additional file 18: Table S13.
Of 10 variants associated with HDL-C and/or ApoA-I,
only one ApoA-I associated variant (rs5888 [p.Ala350Ala]
in exon 8) showed suggestive evidence of regulatory func-
tion with a score of 3a (Table 4).
Of 10 novel variants, one insertion variant (p1048insC/
chr12:125348472) located in 5′ UTR-exon 1 had a
strong potential for regulatory function with a score of
2a (Additional file 4: Table S4).
Comparison of SCARB1 single-site and haplotype association
analysis results between African Blacks (this study) and US
Non-Hispanic Whites (previous study [49])
We compared SCARB1 single-site and haplotype associ-
ation results in African Blacks reported in this study to
those in US Non-Hispanic Whites (NHWs) reported in
our previously published study [49]. In the sequencing
stage, the number of variants identified in African Blacks
(n = 83) was greater than that in US NHWs (n = 44).
Notably, most (~90 %) of the 22 sequence variants that
were shared between the two populations differed in
minor alleles and/or MAFs. Although our major findings
included the associations with HDL-C and ApoA-I in
African Blacks, we also sought to replicate four associa-
tions observed with ApoB levels in US NHWs [49]
(Table 9); the association between rs11057820 and ApoB
(P < 0.05) that we previously reported in US NHWs [49]
was also observed in African Blacks (US NHWs [G
allele]: β = 0.8700, P = 0.0436; African Blacks [A allele]:
β = 1.8661, P = 0.0292). In addition, we observed two
variants (rs4765615 and rs701106) exhibiting nominal
associations (P < 0.05) in both populations, albeit with
different lipid traits (US NHWs| rs4765615 [G allele]: β
= 1.2493, P = 0.0059 for ApoB; rs701106 [T allele]: β =
0.0394, P = 0.0066 for HDL-C; African Blacks|
rs4765615 [A allele]: β = −0.4646, P = 0.013 for HDL-C
and β = −0.9139, P = 0.048 for ApoA-I; rs701106 [T al-
lele]: β = 1.2967, P = 0.0156 for ApoA-I). Moreover, we
noticed that two regions associated with HDL-C or
ApoA-I (global P < 0.05; Table 10) in African Blacks
spanning intron 2 and intron 3 overlapped with the
ApoB-associated region (Region I in Fig. 4) previously
reported in US NHWs [49]. Three haplotype regions as-
sociated with HDL-C (global P < 0.05) spanning intron
11 and exon 13-3′ UTR in African Blacks also over-
lapped with a large HDL-C-associated region (Region II
in Fig. 4) previously reported in US NHWs [49].
Discussion
Our sequencing identified 83 variants, of which 78 were
selected for follow-up genotyping in the total sample of
Table 5 Association results for low-frequency and rare SCARB1 variants (MAF <5 %)
MAF No of
Variants
No of Samples with/
without Variants
HDL-C ApoA-I
Stat P Stat P
≤0.01 23a 93/694 126653.8207 0.0478 60151.0985 0.3707
≤0.02 26 134/653 123009.0805 0.1324 48439.6697 0.5166
<0.05 43 442/346 135697.1974 0.0737 298813.0544 0.1517
ApoA-I apolipoprotein A-I, HDL-C high-density lipoprotein cholesterol, MAF minor allele frequency, SD standard deviation, SNP single nucleotide polymorphism
Results were adjusted for covariates: sex, age, waist, current smoking (yes/no), and minutes of walking or biking to work each day (jobmin) for HDL-C; sex and age
for ApoA-I
Nominally significant P-values (P < 0.05) are shown in bold
aIncluding p70201/chr12:125279319 that was observed in one individual with an outlier value (above the mean + 3.5 SD). See details in Result Section 3.5
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Table 6 Characteristics and effects of 6 SCARB1 rare variants of interest














p52919 125296601 Intron 4 5 G/T 0.0013 GG 734 47.87 ± 12.71 −7.4063 2.5863 1.1050 0.0043 0.1465 ApoA-I (↓)
GT 2 (0.27) 24.67 ± 9.26
p53372 rs115604379 125296148 Intron 5 5 C/T 0.0066 CC 729 47.68 ± 12.64 3.0372 1.1642 0.9140 0.0093 0.2190
CT 10 (1.35) 58.2 ± 13.03
p54611 125294909 Intron 5 4 T/C 0.0007 TT 742 47.86 ± 12.68 −9.5243 3.6710 0.8920 0.0097 0.2190 ApoA-I (↓)
TC 1 (0.13) 19.59 ± NA
p54856 125294664 Intron 6 4 C/T 0.0007 CC 742 47.85 ± 12.70 −8.4305 3.6579 0.7130 0.0215 0.3243 ApoA-I (↓)
CT 1 (0.13) 21.48 ± NA
p77620 rs377124254 125271900 Intron 10 5 G/A 0.0007 GG 735 47.77 ± 12.67 11.5518 3.6514 1.3500 0.0016 0.1104
GA 1 (0.14) 90.2 ± NA
p82264 rs141545424 125267256 Exon 12 Gly501Gly 5 C/A 0.0007 CC 739 47.77 ± 12.66 11.5850 3.6469 1.3530 0.0016 0.1104
CA 1 (0.14) 90.31 ± NA
ApoA-I
p52919 125296601 Intron 4 5 G/T 0.0013 GG 741 136.81 ± 27.74 −13.4137 6.4689 0.5750 0.0385 0.4359 HDL-C (↓)
GT 2 (0.27) 97.42 ± 18.38
p54611 125294909 Intron 5 4 T/C 0.0007 TT 748 136.83 ± 27.66 −19.2831 9.0970 0.5980 0.0344 0.4359 HDL-C (↓)
TC 1 (0.13) 80.62 ± NA
p54856 125294664 Intron 6 4 C/T 0.0007 CC 748 136.87 ± 27.61 −24.0757 9.0781 0.9330 0.0082 0.2918 HDL-C (↓)
CT 1 (0.13) 67.98 ± NA
ApoA-I apolipoprotein A-I, FDR false discovery rate, GT genotype, HDL-C high-density lipoprotein cholesterol, MAF minor allele frequency, RegDB RegulomeDB, SD standard deviation, SE standard error, SNP single
nucleotide polymorphism; R2, the proportion of the phenotypic variance explained by the variant; ↓, decreased
All alleles were on reverse stand. HDL-C and ApoA-I variables were in mg/dL and Box-Cox transformed
Results were adjusted for covariates: sex, age, waist, current smoking (yes/no), and minutes of walking or biking to work each day (jobmin) for HDL-C; sex and age for ApoA-I.
Detailed single-site association results are shown in Additional file 14: Table S9 and Additional file 15: Table S10.
a, cRefSeq of SCARB1: hg19, NM_005505 (CHIP Bioinformatics)
bdbSNP build 139: GRCh37.p10. All 10 novel variants identified in this study have been submitted to dbSNP (batch ID: SCARB1_AB): http://www.ncbi.nlm.nih.gov/SNP/snp_viewTable.cgi?handle=KAMBOH














Table 7 Significant haplotype association (global P < 0.05) of 136 SCARB1 genotyped variants with HDL-C and ApoA-I
Wind
#


















39 p41632-rs6488943 125307888 Intron 1 A/C 0.2954 −0.2195 0.3244 h39.1 CCGG 0.0315 0.4305 0.6471 0.6654 0.5060 0.0207
39 p42467-rs11057830 125307053 Intron 1 C/T 0.1523 −0.2810 0.3015 h39.2 CCGA 0.2508 −0.5918 0.2725 −2.1713 0.0302
39 p45516-rs1902569 125304004 Intron 1 G/A 0.1544 0.5447 0.0386 h39.3 ATGA 0.1414 −0.6841 0.3192 −2.1433 0.0324
39 p45627-rs12297372 125303893 Intron 1 A/G 0.0487 −0.0483 0.9156 h39.4 ACAA 0.1514 0.1991 0.2963 0.6720 0.5018
h39.5 ACGG 0.0155 −1.7144 0.9080 −1.8880 0.0594
h39.6 (rare) **** 0.0148 2.5239 1.0902 2.3151 0.0209
hap.base39 ACGA 0.3946 NA NA NA NA
44 p48969-rs2343394 125300551 Intron 2 C/T 0.1898 0.3165 0.1788 h44.1 TCWG 0.1855 0.5292 0.2523 2.0977 0.0363 0.0271
44 p49537-rs7305310 125299983 Intron 2 C/T 0.1007 −0.3396 0.2566 h44.2 CCDG 0.2244 0.4676 0.2429 1.9249 0.0546
44 p49570delC-rs145376237 125299950 Intron 2 W/D 0.2276 0.3121 0.1773 h44.3 CCWG 0.0446 1.0491 0.4882 2.1489 0.0320
44 p49690-rs4765615 125299830 Intron 2 G/A 0.4426 −0.4646 0.0130 h44.4 CTWG 0.1018 −0.1197 0.3121 −0.3835 0.7015
h44.5 (rare) **** 0.0089 −0.9887 1.0998 −0.8990 0.3689
hap.base44 CCWA 0.4348 NA NA NA NA
45 p49537-rs7305310 125299983 Intron 2 C/T 0.1007 −0.3396 0.2566 h45.1 CDGC 0.2282 0.4661 0.2393 1.9473 0.0519 0.0155
45 p49570delC-rs145376237 125299950 Intron 2 W/D 0.2276 0.3121 0.1773 h45.2 CWGC 0.2302 0.6926 0.2376 2.9146 0.0037
45 p49690-rs4765615 125299830 Intron 2 G/A 0.4426 −0.4646 0.0130 h45.3 TWGC 0.1020 −0.0653 0.3085 −0.2115 0.8325
45 p49759-rs146272788 125299761 Intron 2 C/T 0.0020 2.5988 0.2219 h45.4 (rare) **** 0.0030 2.0667 2.0848 0.9913 0.3219
hap.base45 CWAC 0.4366 NA NA NA NA
46 p49570delC-rs145376237 125299950 Intron 2 W/D 0.2276 0.3121 0.1773 h46.1 DGCG 0.2228 0.4373 0.2413 1.8123 0.0703 0.0278
46 p49690-rs4765615 125299830 Intron 2 G/A 0.4426 −0.4646 0.0130 h46.2 WGCG 0.3311 0.4910 0.2105 2.3326 0.0199
46 p49759-rs146272788 125299761 Intron 2 C/T 0.0020 2.5988 0.2219 h46.3 (rare) **** 0.0080 1.9089 1.0569 1.8061 0.0713
46 p49978-rs5891 125299542 Exon 3 Val135lle G/A 0.0058 1.3374 0.2791 hap.base46 WACG 0.4381 NA NA NA NA
47 p49690-rs4765615 125299830 Intron 2 G/A 0.4426 −0.4646 0.0130 h47.1 ACGG 0.4346 −0.4701 0.1824 −2.5777 0.0101 0.0079
47 p49759-rs146272788 125299761 Intron 2 C/T 0.0020 2.5988 0.2219 h47.2 (rare) **** 0.0101 1.4683 0.9441 1.5552 0.1203
47 p49978-rs5891 125299542 Exon 3 Val135lle G/A 0.0058 1.3374 0.2791 hap.base47 GCGG 0.5553 NA NA NA NA
47 p50024-rs368880622 125299496 Intron 3 G/T 0.0026 1.6506 0.4362
63 p53359-rs112371713 125296161 Intron 5 G/A 0.1243 0.4193 0.1651 h63.1 ACGA 0.1237 0.3273 0.3011 1.0871 0.2773 0.0394
63 p53372-rs115604379 125296148 Intron 5 C/T 0.0066 3.0372 0.0093 h63.2 GCGG 0.0427 −0.1630 0.4738 −0.3441 0.7309














Table 7 Significant haplotype association (global P < 0.05) of 136 SCARB1 genotyped variants with HDL-C and ApoA-I (Continued)
63 p54445-rs60910935 125295075 Intron 5 A/G 0.0418 −0.1247 0.7963 h63.4 (rare) **** 0.0068 2.9428 1.2559 2.3432 0.0194
hap.base63 GCGA 0.5591 NA NA NA NA
72 p55923-rs838900 125293597 Intron 6 G/A 0.3921 0.2787 0.1549 h72.1 ACAG 0.2725 0.4039 0.2520 1.6024 0.1095 0.0315
72 p55963-rs7134858 125293557 Intron 6 C/T 0.1560 0.4418 0.0799 h72.2 ACGG 0.1086 −0.1763 0.3929 −0.4486 0.6538
72 p56845-rs838902 125292675 Intron 6 A/G 0.4249 −0.0786 0.6801 h72.3 GTAG 0.1284 0.3877 0.3170 1.2228 0.2218
72 p57004-rs187562853 125292516 Intron 6 G/A 0.0098 1.6474 0.0872 h72.4 GTGG 0.0297 0.8722 0.6546 1.3323 0.1832
h72.5 GCAG 0.1716 −0.4913 0.3344 −1.4690 0.1422
h72.6 (rare) **** 0.0101 1.7731 0.9506 1.8653 0.0625
hap.base72 GCGG 0.2791 NA NA NA NA
111 p78747-rs2293440 125270773 Intron 11 T/C 0.4112 −0.1684 0.3806 h111.1 CCCG 0.0306 0.7458 0.5599 1.3321 0.1832 0.0040
111 p78791-rs75289200 125270729 Intron 11 T/C 0.0321 0.7037 0.2078 h111.2 CTGC 0.1534 −0.5556 0.2830 −1.9629 0.0500
111 p79721-rs838896 125269799 Intron 11 G/C 0.3104 0.3565 0.0817 h111.3 CTCG 0.2269 0.1234 0.2391 0.5162 0.6058
111 p79828-rs838895 125269692 Intron 11 C/G 0.3171 0.4961 0.0162 h111.4 TTGG 0.0180 2.3022 0.7617 3.0225 0.0026
h111.5 TTCG 0.0439 0.5755 0.5317 1.0823 0.2795
h111.6 TTCC 0.0145 0.9606 0.8068 1.1907 0.2342
h111.7 (rare) **** 0.0033 0.7755 2.1917 0.3538 0.7236
hap.base111 TTGC 0.5094 NA NA NA NA
112 p78791-rs75289200 125270729 Intron 11 T/C 0.0321 0.7037 0.2078 h112.1 CCGA 0.0311 0.7440 0.5559 1.3384 0.1812 0.0055
112 p79721-rs838896 125269799 Intron 11 G/C 0.3104 0.3565 0.0817 h112.2 TGGA 0.0171 2.3734 0.7506 3.1621 0.0016
112 p79828-rs838895 125269692 Intron 11 C/G 0.3171 0.4961 0.0162 h112.3 TGCA 0.0112 −1.2672 0.9074 −1.3964 0.1630
112 p80045-rs838893 125269475 Intron 11 G/A 0.3244 0.3127 0.1224 h112.4 TCGA 0.2704 0.2488 0.2164 1.1501 0.2505
h112.5 TCCG 0.0139 1.1219 0.8186 1.3704 0.1710
h112.6 (rare) **** 0.0068 1.6244 1.2691 1.2800 0.2009
hap.base112 TGCG 0.6493 NA NA NA NA
113 p79721-rs838896 125269799 Intron 11 G/C 0.3104 0.3565 0.0817 h113.1 GGAG 0.0171 2.3949 0.7509 3.1895 0.0015 0.0048
113 p79828-rs838895 125269692 Intron 11 C/G 0.3171 0.4961 0.0162 h113.2 GCAG 0.0120 −1.1963 0.8784 −1.3619 0.1736
113 p80045-rs838893 125269475 Intron 11 G/A 0.3244 0.3127 0.1224 h113.3 CGAG 0.2996 0.3071 0.2067 1.4861 0.1377
113 p81863-rs185445624 125267657 Intron 11 G/A 0.0020 −0.9612 0.6510 h113.4 CCGG 0.0139 1.1509 0.8168 1.4090 0.1592
h113.5 (rare) **** 0.0081 1.1622 1.0896 1.0666 0.2865
hap.base113 GCGG 0.6493 NA NA NA NA
114 p79828-rs838895 125269692 Intron 11 C/G 0.3171 0.4961 0.0162 h114.1 GAGC 0.3173 0.3755 0.2023 1.8559 0.0639 0.0447














Table 7 Significant haplotype association (global P < 0.05) of 136 SCARB1 genotyped variants with HDL-C and ApoA-I (Continued)
114 p81863-rs185445624 125267657 Intron 11 G/A 0.0020 −0.9612 0.6510 h114.3 CAGC 0.0111 −1.2612 0.9170 −1.3754 0.1694
114 p82019-rs838890 125267501 Intron 11 C/T 0.0320 −1.0051 0.0618 h114.4 (rare) **** 0.0086 0.9073 1.0936 0.8296 0.4070
hap.base114 CGGC 0.6325 NA NA NA NA
117 p82019-rs838890 125267501 Intron 11 C/T 0.0320 −1.0051 0.0618 h117.1 CCAG 0.0238 −1.0596 0.6275 −1.6884 0.0917 0.0433
117 p82264-rs141545424 125267256 Exon 12 Gly501Gly C/A 0.0007 11.5850 0.0016 h117.2 TCGG 0.0311 −0.9657 0.5302 −1.8215 0.0689
117 p82340-rs77483223 125267180 Intron 12 G/A 0.0231 −1.0458 0.1012 h117.3 (rare) **** 0.0067 1.6191 1.2946 1.2507 0.2114
117 p82369-rs75446635 125267151 Intron 12 G/A 0.0059 0.5896 0.6322 hap.base117 CCGG 0.9383 NA NA NA NA
118 p82264-rs141545424 125267256 Exon 12 Gly501Gly C/A 0.0007 11.5850 0.0016 h118.1 CAGT 0.0238 −1.0621 0.6274 −1.6929 0.0909 0.0375
118 p82340-rs77483223 125267180 Intron 12 G/A 0.0231 −1.0458 0.1012 h118.2 CGGC 0.0307 −1.0134 0.5313 −1.9073 0.0569
118 p82369-rs75446635 125267151 Intron 12 G/A 0.0059 0.5896 0.6322 h118.3 (rare) **** 0.0067 1.6189 1.2762 1.2685 0.2050
118 p82434-rs838889 125267086 Intron 12 T/C 0.0315 −1.0389 0.0526 hap.base118 CGGT 0.9387 NA NA NA NA
123 p83884-rs701106 125265636 Intron 12 C/T 0.2597 0.2471 0.2601 h123.1 TCCT 0.0256 −1.2114 0.6218 −1.9483 0.0518 0.0386
123 p86245-rs188375019 125263275 Intron 12 C/T 0.0341 0.7447 0.1639 h123.2 TCCG 0.2327 0.5306 0.2403 2.2085 0.0275
123 p86276-rs747155 125263244 Intron 12 C/T 0.1495 0.2793 0.2980 h123.3 CCTG 0.1476 0.3955 0.2811 1.4071 0.1598
123 p86316-rs701104 125263204 Intron 12 G/T 0.0487 −0.9838 0.0286 h123.4 CCCT 0.0233 −0.2329 0.7038 −0.3309 0.7408
h123.5 CTCG 0.0330 0.8888 0.5458 1.6283 0.1039
h123.6 (rare) **** 0.0029 1.1191 3.2961 0.3395 0.7343
hap.base123 CCCG 0.5348 NA NA NA NA
124 p86245-rs188375019 125263275 Intron 12 C/T 0.0341 0.7447 0.1639 h124.1 CTGA 0.1476 0.1530 0.2692 0.5683 0.5700 0.0368
124 p86276-rs747155 125263244 Intron 12 C/T 0.1495 0.2793 0.2980 h124.2 CCTG 0.0465 −1.1879 0.4699 −2.5281 0.0117
124 p86316-rs701104 125263204 Intron 12 G/T 0.0487 −0.9838 0.0286 h124.3 CCGA 0.0915 0.1086 0.3376 0.3218 0.7477
124 p86481-rs701103 125263039 Exon 13-3' UTR Gly499Arg
(isoform 2)
G/A 0.2451 0.1642 0.4492 h124.4 TCGG 0.0337 0.7348 0.5362 1.3702 0.1710
h124.5 (rare) **** 0.0045 4.0859 2.1131 1.9336 0.0535
hap.base124 CCGG 0.6761 NA NA NA NA
125 p86276-rs747155 125263244 Intron 12 C/T 0.1495 0.2793 0.2980 h125.1 TGAA 0.1476 0.1543 0.2689 0.5737 0.5664 0.0307
125 p86316-rs701104 125263204 Intron 12 G/T 0.0487 −0.9838 0.0286 h125.2 CTGA 0.0465 −1.1980 0.4691 −2.5535 0.0109
125 p86481-rs701103 125263039 Exon 13-l3' UTR Gly499Arg
(isoform 2)
G/A 0.2451 0.1642 0.4492 h125.3 CGAA 0.0915 0.1139 0.3375 0.3375 0.7359
125 p86967-rs187492239 125262553 Exon 13-3' UTR A/G 0.0355 0.7743 0.1412 h125.4 CGGG 0.0352 0.7974 0.5241 1.5216 0.1285














Table 7 Significant haplotype association (global P < 0.05) of 136 SCARB1 genotyped variants with HDL-C and ApoA-I (Continued)
hap.base125 CGGA 0.6747 NA NA NA NA
ApoA-I
47 p49690-rs4765615 125299830 Intron 2 G/A 0.4426 −0.9139 0.0480 h47.1 ACGG 0.4351 −0.8907 0.4584 −1.9432 0.0524 0.0343
47 p49759-rs146272788 125299761 Intron 2 C/T 0.0020 1.5883 0.7630 h47.2 (rare) **** 0.0106 3.5858 2.2998 1.5592 0.1194
47 p49978-rs5891 125299542 Exon 3 Val135lle G/A 0.0058 5.6762 0.0628 hap.base47 GCGG 0.5543 NA NA NA NA
47 p50024-rs368880622 125299496 Intron 3 G/T 0.0026 1.6012 0.7255
48 p49759-rs146272788 125299761 Intron 2 C/T 0.0020 1.5883 0.7630 h48.1 CGGT 0.0206 3.3555 1.6564 2.0258 0.0431 0.0293
48 p49978-rs5891 125299542 Exon 3 Val135lle G/A 0.0058 5.6762 0.0628 h48.2 (rare) **** 0.0106 4.0750 2.3644 1.7235 0.0852
48 p50024-rs368880622 125299496 Intron 3 G/T 0.0026 1.6012 0.7255 hap.base48 CGGC 0.9688 NA NA NA NA
48 p50118-rs58710319 125299402 Intron 3 C/T 0.0208 3.1376 0.0571
49 p49978-rs5891 125299542 Exon 3 Val135lle G/A 0.0058 5.6762 0.0628 h49.1 GGTT 0.0213 3.3792 1.6416 2.0584 0.0399 0.0289
49 p50024-rs368880622 125299496 Intron 3 G/T 0.0026 1.6012 0.7255 h49.2 GGCC 0.1928 0.8864 0.5841 1.5176 0.1295
49 p50118-rs58710319 125299402 Intron 3 C/T 0.0208 3.1376 0.0571 h49.3 (rare) **** 0.0086 4.7388 3.1873 1.4868 0.1375
49 p50151-rs2278986 125299369 Intron 3 T/C 0.1933 0.8568 0.1419 hap.base49 GGCT 0.7774 NA NA NA NA
70 p54627-chr12_125294893 125294893 Intron 5 G/C 0.0020 3.6910 0.4850 h70.1 GCAC 0.3873 0.8579 0.5090 1.6854 0.0923 0.0140
70 p54856-chr12_125294664 125294664 Intron 6 C/T 0.0007 −24.0757 0.0082 h70.2 GCGT 0.1568 2.0940 0.6700 3.1254 0.0018
70 p55923-rs838900 125293597 Intron 6 G/A 0.3921 0.3606 0.4549 h70.3 (rare) **** 0.0027 −2.5567 5.2200 −0.4898 0.6244
70 p55963-rs7134858 125293557 Intron 6 C/T 0.1560 1.7537 0.0052 hap.base70 GCGC 0.4532 NA NA NA NA
71 p54856-chr12_125294664 125294664 Intron 6 C/T 0.0007 −24.0757 0.0082 h71.1 CACA 0.2736 0.7883 0.6210 1.2694 0.2047 0.0488
71 p55923-rs838900 125293597 Intron 6 G/A 0.3921 0.3606 0.4549 h71.2 CACG 0.1134 1.1284 0.9724 1.1604 0.2462
71 p55963-rs7134858 125293557 Intron 6 C/T 0.1560 1.7537 0.0052 h71.3 CGTA 0.1296 2.1103 0.7906 2.6691 0.0078
71 p56845-rs838902 125292675 Intron 6 A/G 0.4249 −0.3052 0.5129 h71.4 CGTG 0.0300 2.1358 1.6772 1.2734 0.2032
h71.5 CGCA 0.1706 −0.1013 0.8355 −0.1212 0.9035
hap.base71 CGCG 0.2822 NA NA NA NA
72 p55923-rs838900 125293597 Intron 6 G/A 0.3921 0.3606 0.4549 h72.1 ACAG 0.2733 0.7471 0.6218 1.2016 0.2299 0.0463
72 p55963-rs7134858 125293557 Intron 6 C/T 0.1560 1.7537 0.0052 h72.2 ACGG 0.1057 0.7094 0.9850 0.7202 0.4716
72 p56845-rs838902 125292675 Intron 6 A/G 0.4249 −0.3052 0.5129 h72.3 GTAG 0.1297 2.0304 0.7898 2.5707 0.0103
72 p57004-rs187562853 125292516 Intron 6 G/A 0.0098 3.2853 0.1690 h72.4 GTGG 0.0299 2.1741 1.6857 1.2897 0.1975
h72.5 GCAG 0.1712 −0.3122 0.8263 −0.3778 0.7057
h72.6 (rare) **** 0.0100 3.9105 2.4373 1.6044 0.1090
hap.base72 GCGG 0.2801 NA NA NA NA














Table 7 Significant haplotype association (global P < 0.05) of 136 SCARB1 genotyped variants with HDL-C and ApoA-I (Continued)
78 p58514-rs838905 125291006 Intron 7 T/C 0.4329 −0.4213 0.3646 h78.2 GTAC 0.0367 1.0784 1.2814 0.8415 0.4003
78 p58664-rs865716 125290856 Intron 7 A/T 0.2708 0.5369 0.3008 h78.3 GTAT 0.2557 0.3365 0.6035 0.5576 0.5773
78 p60255-rs3782287 125289265 Intron 7 C/T 0.2831 0.3715 0.4856 h78.4 GTTC 0.2463 0.4962 0.5864 0.8462 0.3977
h78.5 GTTT 0.0238 5.5715 1.6643 3.3477 0.0009
h78.6 (rare) **** 0.0075 0.6333 2.9303 0.2161 0.8289
hap.base78 ACAC 0.3740 NA NA NA NA
79 p58514-rs838905 125291006 Intron 7 T/C 0.4329 −0.4213 0.3646 h79.1 CACT 0.1270 0.3290 0.8318 0.3955 0.6926 0.0256
79 p58664-rs865716 125290856 Intron 7 A/T 0.2708 0.5369 0.3008 h79.2 TACC 0.0379 0.6384 1.2921 0.4941 0.6214
79 p60255-rs3782287 125289265 Intron 7 C/T 0.2831 0.3715 0.4856 h79.3 TATC 0.2563 0.1851 0.6336 0.2921 0.7703
79 p61872-rs838909 125287648 Intron 7 C/T 0.2199 0.9232 0.1056 h79.4 TTCC 0.1587 −0.6020 0.7769 −0.7749 0.4386
h79.5 TTCT 0.0880 1.8902 0.8856 2.1342 0.0331
h79.6 TTTC 0.0238 5.1755 1.6851 3.0714 0.0022
h79.7 (rare) **** 0.0059 1.2466 3.1079 0.4011 0.6885
hap.base79 CACC 0.3024 NA NA NA NA
80 p58664-rs865716 125290856 Intron 7 A/T 0.2708 0.5369 0.3008 h80.1 ACCG 0.0389 −0.3521 1.2793 −0.2753 0.7832 0.0030
80 p60255-rs3782287 125289265 Intron 7 C/T 0.2831 0.3715 0.4856 h80.2 ACTG 0.1274 −0.1816 0.7909 −0.2297 0.8184
80 p61872-rs838909 125287648 Intron 7 C/T 0.2199 0.9232 0.1056 h80.3 ATCG 0.2611 −0.1400 0.6323 −0.2213 0.8249
80 p62140-rs838910 125287380 Intron 7 G/T 0.3047 −0.0755 0.8821 h80.4 TCCG 0.1549 −1.3614 0.7489 −1.8178 0.0695
h80.5 TCTG 0.0901 2.0511 0.8921 2.2992 0.0218
h80.6 TTCG 0.0224 4.7307 1.8842 2.5107 0.0123
h80.7 (rare) **** 0.0083 3.1429 3.4362 0.9147 0.3607
hap.base80 ACCT 0.2970 NA NA NA NA
81 p60255-rs3782287 125289265 Intron 7 C/T 0.2831 0.3715 0.4856 h81.1 CCGC 0.1740 −1.5355 0.7276 −2.1103 0.0352 0.0050
81 p61872-rs838909 125287648 Intron 7 C/T 0.2199 0.9232 0.1056 h81.2 CCGT 0.0215 −0.5623 1.6155 −0.3481 0.7279
81 p62140-rs838910 125287380 Intron 7 G/T 0.3047 −0.0755 0.8821 h81.3 CCTC 0.0352 3.6130 1.4518 2.4886 0.0130
81 p62409-rs838911 125287111 Intron 7 C/T 0.4211 −0.6245 0.1888 h81.4 CCTT 0.2683 −0.7498 0.6337 −1.1832 0.2371
h81.5 CTGC 0.0886 1.4787 0.9259 1.5970 0.1107
h81.6 CTGT 0.1287 −0.2477 0.7967 −0.3109 0.7560
h81.7 (rare) **** 0.0017 4.9120 8.4190 0.5834 0.5598
hap.base81 TCGC 0.2819 NA NA NA NA
82 p61872-rs838909 125287648 Intron 7 C/T 0.2199 0.9232 0.1056 h82.1 CGTT 0.0214 0.3707 1.6055 0.2309 0.8175 0.0137














Table 7 Significant haplotype association (global P < 0.05) of 136 SCARB1 genotyped variants with HDL-C and ApoA-I (Continued)
82 p62409-rs838911 125287111 Intron 7 C/T 0.4211 −0.6245 0.1888 h82.3 CTTT 0.2692 −0.2007 0.5674 −0.3537 0.7237
82 p62615-rs7138386 125286905 Intron 7 T/C 0.1137 −0.6495 0.3851 h82.4 TGCT 0.0869 2.1488 0.8777 2.4481 0.0146
h82.5 TGTT 0.0179 3.0085 1.9599 1.5351 0.1252
h82.6 TGTC 0.1116 −0.1961 0.7815 −0.2510 0.8019
h82.7 (rare) **** 0.0020 −4.7635 9.0097 −0.5287 0.5972
hap.base82 CGCT 0.4546 NA NA NA NA
83 p62140-rs838910 125287380 Intron 7 G/T 0.3047 −0.0755 0.8821 h83.1 GCTA 0.0854 2.0624 0.8886 2.3211 0.0205 0.0187
83 p62409-rs838911 125287111 Intron 7 C/T 0.4211 −0.6245 0.1888 h83.2 GTTG 0.0389 1.3667 1.2527 1.0910 0.2756
83 p62615-rs7138386 125286905 Intron 7 T/C 0.1137 −0.6495 0.3851 h83.3 GTCG 0.1129 −0.3143 0.7855 −0.4002 0.6891
83 p63483-rs838912 125286037 Intron 7 G/A 0.0867 1.8700 0.0234 h83.4 TCTG 0.0368 3.8488 1.3757 2.7977 0.0053
h83.5 TTTG 0.2675 −0.1681 0.5759 −0.2918 0.7705
h83.6 (rare) **** 0.0031 −0.5696 5.5038 −0.1035 0.9176
hap.base83 GCTG 0.4554 NA NA NA NA
86 p63483-rs838912 125286037 Intron 7 G/A 0.0867 1.8700 0.0234 h86.1 ATCG 0.0871 2.5431 0.8550 2.9743 0.0030 0.0290
86 p64772-rs5888 125284748 Exon 8 Ala350Ala C/T 0.0961 2.0962 0.0080 h86.2 GCAG 0.1457 0.3613 0.6957 0.5194 0.6037
86 p64923-rs838915 125284597 Intron 8 C/A 0.1435 −0.3684 0.5766 h86.3 GCCA 0.2814 1.0972 0.5782 1.8976 0.0581
86 p65999-rs12819677 125283521 Intron 8 G/A 0.2813 0.6769 0.2052 h86.4 GTCG 0.0116 1.6563 2.1240 0.7798 0.4357
hap.base86 GCCG 0.4736 NA NA NA NA
95 p71867-rs7954022 125277653 Intron 9 C/T 0.1323 0.8502 0.2241 h95.1 TACT 0.1311 0.8202 0.7688 1.0669 0.2864 0.0131
95 p72197-rs838861 125277323 Intron 9 A/G 0.3777 −0.1507 0.7464 h95.2 CACC 0.0507 0.3188 1.2809 0.2489 0.8035
95 p72777-rs838862 125276743 Intron 9 C/T 0.0887 0.7012 0.3938 h95.3 CGCT 0.1846 −0.7832 0.6960 −1.1253 0.2608
95 p75766-rs838866 125273754 Intron 9 T/C 0.2116 −0.0497 0.9306 h95.4 CGCC 0.1022 0.7176 0.8581 0.8362 0.4033
h95.5 CGTT 0.0324 4.7525 1.5071 3.1534 0.0017
h95.6 CGTC 0.0582 −1.3987 1.0854 −1.2887 0.1979
h95.7 (rare) **** 0.0009 18.2723 NA NA NA
hap.base95 CACT 0.4399 NA NA NA NA
96 p72197-rs838861 125277323 Intron 9 A/G 0.3777 −0.1507 0.7464 h96.1 ACCT 0.0443 1.0796 1.2832 0.8413 0.4004 0.0484
96 p72777-rs838862 125276743 Intron 9 C/T 0.0887 0.7012 0.3938 h96.2 GCTC 0.1849 −0.7979 0.6554 −1.2176 0.2238
96 p75766-rs838866 125273754 Intron 9 T/C 0.2116 −0.0497 0.9306 h96.3 GCCT 0.0727 −0.3866 0.9478 −0.4079 0.6835
96 p75778-rs7301120 125273742 Intron 9 C/T 0.1135 0.3767 0.6174 h96.4 GCCC 0.0282 1.9372 1.6107 1.2027 0.2295
h96.5 GTTC 0.0319 4.2363 1.4400 2.9419 0.0034














Table 7 Significant haplotype association (global P < 0.05) of 136 SCARB1 genotyped variants with HDL-C and ApoA-I (Continued)
h96.7 (rare) **** 0.0058 −3.2342 3.8265 −0.8452 0.3983
hap.base96 ACTC 0.5728 NA NA NA NA
97 p72777-rs838862 125276743 Intron 9 C/T 0.0887 0.7012 0.3938 h97.1 CTCT 0.1997 −1.0781 0.6237 −1.7287 0.0843 0.0098
97 p75766-rs838866 125273754 Intron 9 T/C 0.2116 −0.0497 0.9306 h97.2 CCTT 0.1141 0.2005 0.7597 0.2639 0.7919
97 p75778-rs7301120 125273742 Intron 9 C/T 0.1135 0.3767 0.6174 h97.3 CCCT 0.0336 0.7963 1.3894 0.5731 0.5667
97 p76757-rs9919713 125272763 Intron 9 A/T 0.4390 −0.1860 0.6921 h97.4 TTCT 0.0301 4.3773 1.4494 3.0201 0.0026
h97.5 TCCT 0.0588 −1.4125 1.0117 −1.3961 0.1631
h97.6 (rare) **** 0.0050 −6.5869 3.6167 −1.8213 0.0690
hap.base97 CTCA 0.5587 NA NA NA NA
109 p78402-rs838898 125271118 Intron 10 G/A 0.0714 −0.9806 0.2889 h109.1 AGCT 0.0288 −1.4134 1.6436 −0.8600 0.3901 0.0195
109 p78430-rs838897 125271090 Intron 10 C/G 0.3830 −0.1887 0.6887 h109.2 AGTT 0.0451 −1.5093 1.2496 −1.2078 0.2275
109 p78747-rs2293440 125270773 Intron 11 T/C 0.4112 −0.2984 0.5352 h109.3 GGCC 0.0317 3.0784 1.3763 2.2366 0.0256
109 p78791-rs75289200 125270729 Intron 11 T/C 0.0321 3.6568 0.0086 h109.4 GGCT 0.1633 −0.4126 0.6911 −0.5971 0.5506
h109.5 GGTT 0.1088 −1.6537 0.8639 −1.9142 0.0560
h109.6 GCCT 0.1851 −1.8104 0.7168 −2.5256 0.0118
hap.base109 GCTT 0.4363 NA NA NA NA
110 p78430-rs838897 125271090 Intron 10 C/G 0.3830 −0.1887 0.6887 h110.1 GCCC 0.0305 3.0357 1.4224 2.1342 0.0331 0.0012
110 p78747-rs2293440 125270773 Intron 11 T/C 0.4112 −0.2984 0.5352 h110.2 GCTG 0.0189 −3.0973 2.2833 −1.3565 0.1753
110 p78791-rs75289200 125270729 Intron 11 T/C 0.0321 3.6568 0.0086 h110.3 GCTC 0.1696 −0.0290 0.6830 −0.0424 0.9662
110 p79721-rs838896 125269799 Intron 11 G/C 0.3104 1.1147 0.0278 h110.4 GTTG 0.1400 −2.3158 0.7741 −2.9914 0.0029
h110.5 GTTC 0.0189 1.3536 2.3385 0.5788 0.5629
h110.6 CCTG 0.1379 −2.4014 0.7888 −3.0443 0.0024
h110.7 CCTC 0.0514 −0.8677 1.2628 −0.6871 0.4922
h110.8 CTTC 0.0398 −0.1892 1.4963 −0.1264 0.8994
h110.9 (rare) **** 0.0012 7.8235 8.0313 0.9741 0.3303
hap.base110 CTTG 0.3918 NA NA NA NA
111 p78747-rs2293440 125270773 Intron 11 T/C 0.4112 −0.2984 0.5352 h111.1 CCCG 0.0305 3.5704 1.4077 2.5364 0.0114 0.0038
111 p78791-rs75289200 125270729 Intron 11 T/C 0.0321 3.6568 0.0086 h111.2 CTGC 0.1514 −2.1697 0.7058 −3.0742 0.0022
111 p79721-rs838896 125269799 Intron 11 G/C 0.3104 1.1147 0.0278 h111.3 CTCG 0.2233 0.3086 0.5985 0.5157 0.6062
111 p79828-rs838895 125269692 Intron 11 C/G 0.3171 1.2206 0.0164 h111.4 TTGG 0.0173 1.0502 1.9388 0.5417 0.5882
h111.5 TTGC 0.0431 0.3464 1.3140 0.2637 0.7921














Table 7 Significant haplotype association (global P < 0.05) of 136 SCARB1 genotyped variants with HDL-C and ApoA-I (Continued)
h111.7 (rare) **** 0.0047 3.8853 4.0634 0.9562 0.3393
hap.base111 TTGC 0.5147 NA NA NA NA
112 p78791-rs75289200 125270729 Intron 11 T/C 0.0321 3.6568 0.0086 h112.1 CCGA 0.0309 3.7315 1.3947 2.6755 0.0076 0.0412
112 p79721-rs838896 125269799 Intron 11 G/C 0.3104 1.1147 0.0278 h112.2 TGGA 0.0179 1.8646 1.8467 1.0097 0.3130
112 p79828-rs838895 125269692 Intron 11 C/G 0.3171 1.2206 0.0164 h112.3 TGCA 0.0109 −3.3720 2.3180 −1.4547 0.1462
112 p80045-rs838893 125269475 Intron 11 G/A 0.3244 0.8859 0.0774 h112.4 TCGA 0.2661 0.7087 0.5428 1.3056 0.1921
h112.5 TCCG 0.0144 1.0316 2.0147 0.5120 0.6088
h112.6 (rare) **** 0.0068 2.8715 3.2105 0.8944 0.3714
hap.base112 TGCG 0.6530 NA NA NA NA
123 p83884-rs701106 125265636 Intron 12 C/T 0.2597 1.2967 0.0156 h123.1 TCCT 0.0235 −1.7638 1.7393 −1.0141 0.3109 0.0468
123 p86245-rs188375019 125263275 Intron 12 C/T 0.0341 1.8399 0.1674 h123.2 TCCG 0.2351 1.8726 0.6006 3.1179 0.0019
123 p86276-rs747155 125263244 Intron 12 C/T 0.1495 −0.2164 0.7433 h123.3 CCTG 0.1485 0.3912 0.6981 0.5604 0.5754
123 p86316-rs701104 125263204 Intron 12 G/T 0.0487 −0.6627 0.5579 h123.4 CCCT 0.0238 1.6476 1.7546 0.9390 0.3480
h123.5 CTCG 0.0328 2.3144 1.3655 1.6949 0.0905
h123.6 (rare) **** 0.0024 1.2704 8.8153 0.1441 0.8855
hap.base123 CCCG 0.5340 NA NA NA NA
ApoA-I apolipoprotein A-I, Coef coefficient, del/D deletion, HDL-C high-density lipoprotein cholesterol, MAF minor allele frequency, NA not analyzed, SE standard error, SNP single nucleotide polymorphism, UTR untrans-
lated region, W wild type allele for deletion on RefSeq
All alleles on the reverse strand. HDL-C and ApoA-I variables were in mg/dL and Box-Cox transformed
Results were adjusted for covariates: sex, age, waist, current smoking (yes/no), and minutes of daily walking or biking to work (jobmin) for HDL-C; sex and age for ApoA-I
SNP 1-SNP 4 for each window are shown as “SNP name-SNP ID/Chromosome 12 Position (for novel variants)”. All 10 novel variants identified in this study have been submitted to dbSNP database (batch ID:
SCARB1_AB): http://www.ncbi.nlm.nih.gov/SNP/snp_viewTable.cgi?handle=KAMBOH.
Nominally significant P-values (P < 0.05) for SNPs with MAF ≥5 % in single-site analysis are shown in bold
Haplotype sequences corresponding to SNP 1-SNP 4 in the 5′ to 3′ direction, respectively
Haplotype association results for all haplotype windows are shown in Additional file 16: Table S11, see haplotype association plots in Fig. 3
a, cRefSeq of SCARB1: hg19, NM_005505 (CHIP Bioinformatics)














Table 8 Significantly associated haplotype regions (global P < 0.05) with HDL-C and ApoA-I




Chr12 Positiona The Composited Variants in the Region, 5′ to 3′ Direction Most Relevant Haplotype
(Location)
Start (5′) End (3′) SNP Nameb-SNP IDc/Chr12 Positiona Major/Minor Alleles Haplotype # Sequence β (Min-Max)
1 HDL-C 44 125300551 125299542 p48969-rs2343394 C/T h44.3 CCWGCGG 0.4910–1.0491
45 (intron 2) (exon 3) p49537-rs7305310 C/T h45.2
46 p49570delC-rs145376237 W/D h46.2
47 p49690-rs4765615 G/A hap.base47
p49759-rs146272788 C/T hap.base44 CCWACGG −0.4701
p49978-rs5891 (p.Val135Ile) G/A hap.base45
p50024-rs368880622 G/T hap.base46
h47.1
2 ApoA-I 47 125299830 125299369 p49690-rs4765615 G/A h47.1 ACGGTT (−0.8907)–3.3792
48 (intron 2) (intron 3) p49759-rs146272788 C/T h48.1




3 ApoA-I 70 125294893 125292516 p54627-chr12_125294893 G/C h70.2 GCGTAG 2.0304–2.1103
71 (intron 5) (intron 6) p54856-chr12_125294664d C/T h71.3




4 ApoA-I 78 125291928 125286037 p57592-rs838903 G/A h78.5 GTTTCGCTG 4.7307–5.5715
79 (intron 7) (intron 7) p58514-rs838905 T/C h79.6
80 p58664-rs865716 A/T h80.6
81 p60255-rs3782287 C/T hap.base81
82 p61872-rs838909 C/T hap.base82
83 p62140-rs838910 G/T hap.base83




















5 ApoA-I 95 125277653 125272763 p71867-rs7954022 C/T h95.5 CGTTCT 4.2363-4.7525
96 (intron 9) (intron 9) p72197-rs838861 A/G h96.5




6* ApoA-I 109 125271118 125269475 p78402-rs838898 G/A h109.6 GCCTGCA (−3.3720)─(−1.8104)
110 (intron 10) (intron 11) p78430-rs838897 C/G h110.6
111 p78747-rs2293440 T/C h111.2




7* HDL-C 111 125270773 125267501 p78747-rs2293440 T/C h111.4 TTGGAGC 0.3755–2.3949
112 (intron 11) (intron 11) p78791-rs75289200 T/C h112.2
113 p79721-rs838896 G/C h113.1




8 HDL-C 117 125267501 125267086 p82019-rs838890 C/T h117.2 TCGGC (−1.0134)–(−0.9657)

















Table 8 Significantly associated haplotype regions (global P < 0.05) with HDL-C and ApoA-I (Continued)
9 HDL-C 123 125265636 125262553 p83884-rs701106 C/T h123.4 CCCTGA (−1.180)–(−0.2329)
124 (intron 12) (exon 13-3′ UTR) p86245-rs188375019 C/T h124.2
125 p86276-rs747155 C/T h125.2
p86316-rs701104 G/T
p86481-rs701103 (p.Gly499Arg, isoform 2) G/A
p86967-rs187492239 A/G
ApoA-I apolipoprotein A-I, del/D deletion, HDL-C high-density lipoprotein cholesterol, SNP single nucleotide polymorphism, UTR untranslated region, W wild type allele for deletion on the RefSeq
All alleles on the reverse strand. HDL-C and ApoA-I variables were in mg/dL and Box-Cox transformed
Results were adjusted for covariates: sex, age, waist, current smoking (yes/no), and minutes of daily walking or biking to work (jobmin) for HDL-C; sex and age for ApoA-I
All nine haplotype regions are shown in Fig. 3
Detailed single-site associations are shown in Additional file 14: Table S9 and Additional file 15: Table S10
Detailed haplotype associations are shown in Table 7 and Additional file 16: Table S11
Regions with asterisk (*) indicate regions that included the haplotype window exhibiting the most significant association signal (the smallest global P) for the associated trait
For each region, the most significant associated haplotype window is shown in bold
SNPs with significant evidence of association with the same trait in both single-site and haplotype analyses (single-site P < 0.05 and global P < 0.05) are shown in bold
SNPs with significant evidence of association with different trait in single-site and haplotype analyses (single-site P < 0.05 and global P < 0.05) are shown in italic bold
a, bRefSeq of SCARB1: hg19, NM_005505 (CHIP Bioinformatics)
cdbSNP build 139: GRCh37.p10














788 African Blacks. Additional 69 tagSNPs from the
HapMap-YRI data along with two previously reported
lipid-associated SCARB1 variants were also genotyped
in the total sample. Of 149 genotyped SCARB1 variants,
137 that passed QC were examined for association with
major lipid traits (Table 2). The initial gene-based analyses
revealed a nominal association with HDL-C (P = 0.0421)
as well as a trend for association with ApoA-I (P = 0.1016;
Fig. 3 Haplotype association plots for HDL-C and ApoA-I. Top: The -log10 P-values are presented in the Y-axis. A total of 136 genotyped variants
are shown in order on SCARB1 gene (5′→ 3′; RefSeq: hg19, NM_005505) in the X-axis. Middle: gene structure of SCARB1. Marker names are shown
as “SNP name-SNP ID/chromosome 12 position (for novel variants)”. Bottom: linkage disequilibrium (LD) plot of 136 variants. SNPs with MAF ≥5 %
are shown in bold. SNP ID is based on dbSNP build 139. All 10 novel variants identified in this study have been submitted to dbSNP (batch ID:
SCARB1_AB): http://www.ncbi.nlm.nih.gov/SNP/snp_viewTable.cgi?handle=KAMBOH. The dash line indicates the significance threshold (global
P = 0.05). Significantly associated haplotype regions are highlighted. The degree of shades and values (r2 × 100) in each square of LD plot
represent the pairwise correlations between 136 genotyped variants: black indicating r2 = 1, white indicating r2 = 0, and shade intensity
indicating r2 between 0 and 1. ApoA-I, apolipoprotein A-I; HDL-C, high-density lipoprotein cholesterol; LD, linkage disequilibrium; MAF,
minor allele frequency; SNP, single nucleotide polymorphism; UTR, untranslated region
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Alleles US Non-Hispanic Whitesa (n = 623) African Blacks (n = 788)
MA, MAF β P MA,
MAF
β P Other Assoc
Trait(s)f(SE) (SE)
HDL-C
p28957 rs11057844 125320563 Intron 1 5 G/A A, 0.1839 −0.0395 0.0035 A, 0.2362 0.3671 0.1075
(0.0135) (0.2278)
p83884 rs701106 125265636 Intron 12 5 C/T T, 0.1527 0.0394 0.0066 T, 0.2597 0.2471 0.2601 ApoA-I
(0.0144) (0.2192)
p87927 rs838880 125261593 3′ flanking 5 G/A G, 0.3237 0.0257 0.0250 A, 0.2414 0.0198 0.9314
(0.0114) (0.2302)
ApoB
p48969 rs2343394 125300551 Intron 2 5 C/T T, 0.2850 1.2544 0.0082 T, 0.1898 0.0383 0.9544
(0.4721) (0.6696)
p49690 rs4765615 125299830 Intron 2 5 G/A G, 0.4497 1.2493 0.0059 A, 0.4426 0.7771 0.1338 HDL-C, ApoA-I
(0.4518) (0.5178)
p50151 rs2278986 125299369 Intron 3 5 T/C C, 0.2890 1.1926 0.0122 C, 0.1933 0.1308 0.8434
(0.4735) (0.6619)
p52556 rs11057820 125296964 Intron 4 5 G/A G, 0.4871 0.8700 0.0436 A, 0.1000 1.8661 0.0292
(0.4300) (0.8542)
ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, MA minor allele, MAF minor allele frequency, RegDB RegulomeDB, SE standard error, SNP single nucleotide polymorphism
All alleles on the reverse strand
HDL-C and ApoB values for US Non-Hispanic Whites were in mg/dL, Box-Cox transformed, and adjusted for covariates: sex, age, body mass index, and smoking (past/current/never) for HDL-C; age and smoking
for ApoB
HDL-C and ApoB values for African Blacks were in mg/dL, Box-Cox transformed, and adjusted for covariates: sex, age, waist, current smoking (yes/no), and daily walking or biking to work (jobmin) for HDL-C; body mass
index and staff status for ApoB
Nominally significant P-values (P < 0.05) are shown in bold
aData from Niemsiri V, et al. Circ Cardiovasc Genet 2014, 7(6):838–847 (Ref [49])
b, dRefSeq of SCARB1: hg19, NM_005505 (CHIP Bioinformatics)
cdbSNP version 139: GRCh37.p10
eThe RegulomeDB (version 1.0) scoring scheme is described at the footnote of Additional file 17: Table S12 or at http://regulome.stanford.edu/help
fEvidence is based on SNPs with MAF ≥5 % exhibiting nominally significant association with either HDL-C or ApoA-I (P < 0.05; Additional file 14: Table S9 and Additional file 15: Table S10) in single-site association














Table 10 Significant lipid-associated regions (global P < 0.05) that were observed in US Non-Hispanic Whites (previous studya) and African Blacks (this study)
Region
#
Consecutive Haplotype Windows in 623 US Non-Hispanic Whitesa Consecutive Haplotype Windows in 788 African Blacks
Trait Chr12 Positionb (Location) Length
(bp)
The Composited Variants, 5′ to 3′ Direction Trait Chr12 Positionb (Location) Length
(bp)
The Composited Variants, 5′ to 3′
Direction
Start (5′) End (3′) SNP Namec-SNP IDd Major/Minor
Alleles
Start (5′) End (3′) SNP Namec-SNP IDd Major/Minor
Alleles
I ApoB 125300551 125299369 1183 p48969-rs2343394 C/T HDL-C 125300551 125299496 1056 p48969-rs2343394 C/T




p49978-rs5891 G/A p49690-rs4765615 G/A
(p.Val135Ile)




ApoA-I 125299830 125299369 462 p49690-rs4765615 G/A






II HDL-C 125269692 125262516 7177 p79828-rs838895 C/G HDL-C 125269692 125267501 2192 p79828-rs838895 C/G
(intron 11) (exon 13- 3′
UTR)
p80045-rs838893 G/A (intron 11) (intron 11) p80045-rs838893 G/A
p83088-rs797729 A/G p81863-rs185445624 G/A
p83884-rs701106 C/T p82019-rs838890 C/T
p86436-rs10396214 C/T HDL-C 125267501 125267086 416 p82019-rs838890 C/T
(p.Arg484Trp, isoform 2)


















Table 10 Significant lipid-associated regions (global P < 0.05) that were observed in US Non-Hispanic Whites (previous studya) and African Blacks (this study) (Continued)
HDL-C 125265636 125262553 3084 p83884-rs701106 C/T








ApoA-I apolipoprotein A-I, ApoB apolipoprotein B, del/D deletion, HDL-C high-density lipoprotein cholesterol, SNP single nucleotide polymorphism, UTR untranslated region, W wild type allele for deletion on RefSeq
All alleles on the reverse strand
Results for a US Non-Hispanic White sample were Box-Cox transformed, and adjusted for covariates: sex, age, body mass index, and smoking (past/current/never) for HDL-C; age and smoking for ApoB
Results for an African Black sample were Box-Cox transformed, and adjusted for covariates: sex, age, waist, current smoking (yes/no), and minutes of walking or biking to work each day (jobmin) for HDL-C; sex and age
for ApoA-I
Location of each region on SCARB1 gene is shown in Fig. 4
SNPs with significant evidence with the same trait in both single-site and haplotype associations (single-site P and global P < 0.05) observed in each population are shown in bold
SNPs with significant evidence with the different trait in single-site and haplotype associations (single-site P and global P < 0.05) in each population are shown in italic bold
aData from Niemsiri V, et al. Circ Cardiovasc Genet 2014, 7(6):838–847 (Ref [49])
b, cRefSeq of SCARB1: hg19, NM_005505 (CHIP Bioinformatics)














Table 3). Consistent with the gene-based results, single-
site association analyses also revealed 10 common variants
nominally associated (P < 0.05) with HDL-C (n = 5) and/or
ApoA-I (n = 8; Table 4 and Fig. 2). The best association
signal was between rs11057851 in intron 1 and HDL-C (P
= 0.0043, FDR = 0.1465) followed by two associations with
ApoA-I including rs7134858 in intron 6 (P = 0.0052, FDR
= 0.2918) and rs5888 (p.Ala350Ala) in exon 8 (P = 0.0080,
FDR = 0.2918). Moreover, three variants (rs11057851,
rs4765615, and rs838895) exhibited evidence of associa-
tions (P < 0.05) with both HDL-C and ApoA-I. These find-
ings are supported by the fact that SCARB1 appears to
influence ApoA-I in addition to HDL-C [15, 17]. In our
data, there was a moderate correlation between ApoA-I
and HDL-C levels (r2 = 0.61).
Except for previously reported association of rs5888
(p.Ala350Ala) with lipid traits (HDL-C or LDL-C) in
non-African populations [30–34, 36, 37, 39], the
remaining nine associations observed in this study with
the lipid traits (HDL-C and/or ApoA-I levels) in general
population are novel and await replication in independ-
ent African or African-derived populations. Two of these
nine SNPs have previously been shown to have differen-
tial effects on cholesterol levels in response to statin
(rs4765615) [50] or on HDL-C/TG levels in response to
estradiol in post-menopausal women (rs838895) [51]. An-
other variant (rs838896) was found to be associated with
decreased SCARB1 expression in liver [51]. Although the
latter SNP was not associated with a low RegulomeDB
score (<3), we cannot rule out the possibility that it might
be affecting the SCARB1 expression in a tissue-specific
manner.
The haplotype analysis revealed evidence of significant
association (global P < 0.05) of 32 haplotype windows
with HDL-C (n = 16) and/or ApoA-I (n = 21; Table 7)
and nine regions harboring consecutive overlapping
Fig. 4 Lipid-associated SCARB1 common variants and haplotype regions identified in US Non-Hispanic Whites (previous study; Ref [49]) and
African Blacks (this study). Lipid-associated variants with MAF ≥5 % with P-values <0.05 and haplotype regions with global P-values < 0.05 that
were previously identified in US Non-Hispanic Whites (US NHWs; n = 623) are shown in top panel and those identified in African Blacks (n = 788)
are shown in bottom panel (see details in Table 9 and Table 10). SCARB1 variants and haplotype regions are shown on SCARB1 gene (5′→ 3′;
RefSeq: hg19, NM_005505). All SNP IDs are based on dbSNP build 139. Regions I and II that are defined based on consecutive haplotype windows
with evidence of lipid-association in US NHWs (global P < 0.05; see details in Ref [49]) also show some significant associations in African Blacks
(global P < 0.05; see details in Table 7 and Table 8). ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol;
MAF, minor allele frequency; NHW, Non-Hispanic White; SNP, single nucleotide polymorphism; UTR, untranslated region
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haplotype windows significantly associated with either
HDL-C (4 regions) or ApoA-I (5 regions; Table 8 and
Fig. 3). In addition, six variants with nominal association
(P < 0.05) in single-site analysis were contained in seven
of these nine significantly associated regions, indicating
the presence of functional variants in these regions. Our
findings demonstrate that haplotype analysis may pro-
vide more information than single-site analysis.
Our comparison of the single-site and haplotype asso-
ciation results between in African Blacks (this study)
and US NHWs (previous study [49]) has revealed three
variants (rs11057820, rs4765615, and rs701106; Table 9)
and two regions (Regions I and II; Table 10 and Fig. 4)
showing evidence of lipid-associations in both ethnic
groups. However, there were differences in associated
traits, and/or associated alleles or their directional ef-
fects between the two ethnic groups, which reflects the
genetic heterogeneity of complex phenotypes like lipid
traits among diverse populations. This phenomenon can
be explained by different ancestry backgrounds associ-
ated with differences in LD structure and genetic archi-
tecture, as well as by differences in SNP-SNP, gene-gene,
and gene-environment interactions. Nonetheless, the
lipid associations observed across different ethnic popula-
tions provide convincing evidence that causal/functional
variants are present in SCARB1 gene that deserves com-
prehensive sequencing and functional studies in order to
confirm and further characterize the effects of its variants
on lipid metabolism.
Rare variant analysis showed significant evidence of
association between a group of 23 rare variants (MAF
≤1 %) and HDL-C (P = 0.0478; Table 5). Single-site ana-
lysis of these rare variants revealed six (including three
novel ones) with effects on HDL-C, of which three also
had effects on ApoA-I (Table 6). In addition, four of
these six rare variants appeared to be carried by individ-
uals with extreme HDL-C and/or ApoA-I levels (above
or under the 3rd percentile). This HDL-C-associated rare
variant group also included a novel variant (p70201/
chr12:125279319) that was observed in one individual
with an unusually high plasma HDL-C level (above the
mean + 3.5 SD). Our findings suggest that these rare vari-
ants might have functional relevance, thus screening of
additional large African samples for these rare variants
may help to establish their role in HDL-C and ApoA-I
metabolism.
To date, there has been limited information concerning
possible functional effects of lipid-associated SCARB1
variants, particularly for those located in non-coding
regions. In fact, most of common and rare HDL-C/ApoA-
I-associated variants observed in the current study are
non-coding and do not show strong evidence of regula-
tory function based on RegulomeDB database. Nonethe-
less, three of these HDL-C/ApoA-I-associated SCARB1
variants (rs5888 [p.Ala350Ala], rs838885, and rs838886)
have been previously demonstrated to influence the
SCARB1 expression [51–53]. Therefore, additional func-
tional studies are needed and may help to determine the
functional nature of the SCARB1-associated variants and
those in LD with them.
Our study has revealed a number of novel findings, al-
though we also acknowledge some limitations. SCARB1
is a large gene and we sequenced only its coding regions
and exon-intron junctions and also our sequencing sam-
ple size was small. Thus, we may have missed some
functional LoF/rare variants due to small sample size
and those located in uncovered intronic regions. More-
over, consistent with generally small effect sizes of lipid-
associated variants reported in the literature, most of
our single-site associations reached nominal significance
(P < 0.05) but did not survive multiple testing correc-
tions. Only the top variant (rs11057851) associated with
HDL-C yielded an FDR cut-off of <0.20 (FDR = 0.1465;
Table 4). Therefore, future larger studies in independent
African or African-derived populations are necessary to
validate all nominal associations observed in this study.
Conclusions
In conclusion, we report the first comprehensive associ-
ation study of SCARB1 variants with lipid traits in a
native African population, which revealed a number of
novel associations in single-site and haplotype analyses.
In addition, resequencing allowed us to identify 10 novel
rare variants, of which four were in the group of 23 rare
variants that has showed association with HDL-C levels.
The SCARB1 associated common and rare variants ob-
served in our study explained ~11.09 % of the variation
in HDL-C levels and ~8.63 % of the variation in ApoA-I
levels. Our findings indicate the genetic contribution of
SCARB1, both common and LoF/rare variants, to inter-
individual lipid variation in the general African Black
population, which warrants further follow-up in inde-
pendent studies. Insights into the HDL-C and related
lipid traits may also lead to new potential targets for
CHD treatment.
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